Immutep Ltd (STU:YP1B)
€ 0.174 0.012 (7.41%) Market Cap: 260.89 Mil Enterprise Value: 149.39 Mil PE Ratio: 9,999.00 PB Ratio: 2.23 GF Score: 39/100

Immutep Ltd Clinical Results Webinar Transcript

Jul 11, 2024 / 11:00PM GMT
Release Date Price: €0.19 (+9.20%)
Paul Sanger
ShareCafe - Moderator

Okay. Good morning, everybody. Good morning, ladies and gentlemen, and thank you for joining us for the Immutep webcast to discuss the company's new clinical data released today regarding Cohort B of the TACTI-003 trial. My name is Paul Sanger, and I will be your moderator today.

(Event Instructions) Let's get started. I would now like to hand over the call to Marc Voigt, Immutep's CEO, to start the presentation. Marc, please go ahead.

Marc Voigt
Immutep Ltd - Chief Executive Officer, Executive Director

Yeah. Thank you, Paul, and welcome, everyone, and we appreciate that you are taking the time again. We are excited to provide this update on TACTI-003 Cohort B on the heels of the oral presentation earlier today at the ESMO virtual plenary session. These ESMO sessions are presentations of the latest original scientific data from clinical trials, and as it relates to Phase IIs, ESMO select trials, which demonstrate remarkable therapeutic benefit, scientific insight, or progress in the area of unmet medical need, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot